Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
argenx SE - American Depositary Shares
(NQ:
ARGX
)
817.47
+13.73 (+1.71%)
Streaming Delayed Price
Updated: 11:08 AM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about argenx SE - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Beyond the Bot: 2026 Marks the Great Rebalancing as Investors Pivot from AI Hype to Tangible Growth
January 02, 2026
As the opening bell rings on January 2, 2026, the financial landscape looks fundamentally different from the AI-crazed atmosphere of the previous two years. The "AI Infrastructure Fever" that dominated...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy
December 31, 2025
As the final trading bell of 2025 rings, the financial markets are closing the year on a high note, characterized by a series of powerful technical breakouts across several high-growth sectors. The S&P...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Earnings Scheduled For October 30, 2025
↗
October 30, 2025
Via
Benzinga
How Do Investors Really Feel About argenx SE?
↗
October 13, 2025
Via
Benzinga
12 Analysts Have This To Say About argenx
↗
September 18, 2025
Via
Benzinga
Is argenx Gaining or Losing Market Support?
↗
September 08, 2025
Via
Benzinga
Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology
December 26, 2025
As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine...
Via
PredictStreet
Topics
Economy
Intellectual Property
ARGENX SE (NASDAQ:ARGX) Combines Minervini Trend Strength with Explosive Fundamental Growth
↗
December 01, 2025
ARGENX (ARGX) stock combines strong technical trends with explosive fundamental growth in EPS and sales, making it a high-momentum candidate for investors.
Via
Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
↗
November 19, 2025
Via
Benzinga
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
↗
November 18, 2025
Via
Benzinga
Argenx SE - ADR (NASDAQ:ARGX) Fits Navellier's 'Little Book' Growth Rules
↗
November 14, 2025
Argenx SE fits a proven growth stock strategy, showing explosive earnings and sales growth, widening margins, and strong cash flow.
Via
Chartmill
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
↗
November 05, 2025
Via
Benzinga
Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports
↗
October 30, 2025
Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls.
Via
Investor's Business Daily
ARGENX SE - ADR (NASDAQ:ARGX) Shows Strong Growth Traits Matching Navellier's Criteria
↗
October 24, 2025
Argenx SE shows strong earnings momentum, soaring revenue growth, and high profitability, aligning with Louis Navellier's systematic growth stock criteria.
Via
Chartmill
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today
↗
October 22, 2025
Via
Benzinga
Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks
↗
October 22, 2025
Motley Fool analysts Karl Thiel, Rick Munarriz, and Tim Beyers offer up three stocks that face dark clouds they can see through.
Via
The Motley Fool
Topics
Workforce
Assessing argenx: Insights From 12 Financial Analysts
↗
October 13, 2025
Via
Benzinga
Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday
↗
October 13, 2025
Via
Benzinga
ARGENX SE - ADR (NASDAQ:ARGX) Matches a Proven Growth Stock Strategy
↗
October 03, 2025
ARGENX stock matches a proven growth strategy, showing explosive earnings revisions, 731% EPS growth, and strong revenue momentum.
Via
Chartmill
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
↗
September 29, 2025
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 7.61% on an annualized basis producing an average annual return of 22.36%. Currently, argenx has a market capitalization of...
Via
Benzinga
Price Over Earnings Overview: argenx
↗
September 26, 2025
In the current market session, argenx Inc. (NASDAQ: ARGX) share price is at $711.62, after a 0.07% increase. Moreover, over the past month, the stock decreased by 0.08%, but in the past year, went up...
Via
Benzinga
Pharma Tariffs Back In Spotlight On New Trump Threat
↗
September 26, 2025
President Donald Trump threatened 100% tariffs on some drug imports.
Via
Investor's Business Daily
Topics
ETFs
Government
World Trade
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
September 19, 2025
Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet...
Via
MarketMinute
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
↗
September 10, 2025
Via
Benzinga
argenx SE - ADR (NASDAQ:ARGX) Fits Louis Navellier's 'Little Book' Growth Strategy
↗
September 10, 2025
Discover argenx SE (ARGX), a top growth stock meeting Louis Navellier's strict criteria with surging earnings, 97% revenue growth, and strong profitability.
Via
Chartmill
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results
↗
September 10, 2025
United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one.
Via
Investor's Business Daily
Topics
ETFs
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
↗
September 08, 2025
The company is working on a treatment for an autoimmune disease that affects the muscles.
Via
Investor's Business Daily
3 Healthcare Pathbreakers With Long-Term Tailwinds
↗
September 01, 2025
These three firms in the fast-changing healthcare sector stand out to analysts for their strong product lineups, defensible technology, and notable pipelines.
Via
MarketBeat
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
↗
August 27, 2025
Via
Benzinga
Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win
↗
August 26, 2025
Argenx advances Vyvgart with strong trial data in seronegative gMG, driving growth projections and reinforcing its leadership in IgG-driven diseases.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
